|
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A loss-of-function approach was used to investigate the effects of small hairpin RNA-mediated knockdown of YAP1 on the expression of RUNX2, CyclinD1, and matrix metalloproteinase-9 (MMP-9) as well as the proliferative activities and invasive potential in OS MG-63 cells (evaluated by MTT and Transwell assays, respectively).
|
23527718 |
2013 |
|
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Elevated expression of Runx2 as a key parameter in the etiology of osteosarcoma.
|
18931939 |
2009 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nontumorigenic human fibroblasts (CCD-45SK and Hs67), peripheral blood lymphocytes, and several human tumor cell lines derived from cervix, colon, and breast carcinomas, epidermoid carcinoma, and osteosarcoma (HeLa, HT29, MCF7, Saos-2, and A431 cell lines) were studied.
|
10608352 |
2000 |
|
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
With real-time polymerase chain reaction, the RUNX2 mRNA level was correlated with BMP-2 mRNA level, and both levels were significantly higher in three osteosarcoma cell lines than in three chondrosarcoma cell lines.
|
21951664 |
2011 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
To study the expression pattern of the target genes from the hotspot amplicon and known candidate genes from 6p12-21, we did quantitative reverse transcription-PCR analysis of MAPK14, MAPK13, CDKN1A, PIM1, MDGA1, BTB9, DNAH8, CCND3, PTK7, CDC5L, and RUNX2 on osteosarcoma patient samples and seven cell lines.
|
18567798 |
2008 |
|
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Using next-generation RNA-sequencing, protein-based assays, as well as the loss- and gain-of-function approaches in selected osteosarcoma cell lines, we show that osteopontin messenger RNA levels closely correlate with RUNX2 expression and that RUNX2 controls the levels of secreted osteopontin.
|
30637720 |
2019 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
We analyzed protein levels and nuclear localization of β-catenin and RUNX2 in a panel of human osteosarcoma cell lines (SAOS, MG63, U2OS, HOS, G292, and 143B).
|
28370561 |
2017 |
|
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Vitamin D Impacts the Expression of Runx2 Target Genes and Modulates Inflammation, Oxidative Stress and Membrane Vesicle Biogenesis Gene Networks in 143B Osteosarcoma Cells.
|
28300755 |
2017 |
|
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Antibodies raised to the unique C-terminal domain were shown to be reactive by immunoprecipitation and immunoblot assay, and were used in confocal immunofluorescence microscopy to reveal low level cytoplasmic staining in osteosarcoma and lymphoma cells that express high levels of Runx2 mRNA.
|
15225881 |
2004 |
|
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our analyses show that the RUNX2 interactome may be constitutively activated in osteosarcoma, and that the downstream intracellular pathways are strongly associated with the regulation of osteoblast differentiation and control of cell cycle and apoptosis in osteosarcoma.
|
19286668 |
2009 |
|
Osteosarcoma of bone
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Stable clones of the human MG63 osteosarcoma cells (MG63-Ap and MG63-IIIc) overexpressing a splice variant form of FGFR2 with or without the S252W mutation (FGFR2IIIcS252W and FGFR2IIIc) showed a higher RUNX2 mRNA expression than parental MG63 cells.
|
15310757 |
2004 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Specifically, subsequenct FISH and qRT-PCR analysis of RUNX2, TUSC3, and PTEN indicated that expression levels correlated with genomic copy number status, showcasing RUNX2 as an OS associated gene and TUSC3 as a possible tumor suppressor candidate.
|
21837709 |
2011 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data underscore the loss of tumor suppressive pathways and activation of specific oncogenic mechanisms associated with osteosarcoma oncogenesis, while drawing attention to the role of RUNX2 expression as a potential biomarker of chemotherapy failure in osteosarcoma.
|
20465837 |
2010 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
RUNX2 (6p21.1) amplification in osteosarcoma.
|
31669178 |
2019 |
|
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
NNT-As1 functions as a cancer-promoting lncRNA by downregulating miR-320a, thus increasing the protein expression level of beta-catenin, RUNX2 and IGF-1R as well as activation of Akt in osteosarcoma.
|
30489194 |
2019 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, RUNX2 binding to diverse gene loci may support the biological properties of osteosarcoma cells.
|
22158627 |
2012 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Based on this knowledge, we found more genes related to the pathogenesis of osteosarcoma and these genes could exert similar function as Runx2, a risk factor confirmed in osteosarcoma, this study may help better understand the genetic mechanism and provide new molecular markers and therapies for osteosarcoma.
|
24293382 |
2014 |
|
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These studies suggest that SERMs can modulate bone-specific cbfa1 gene expression in a human osteosarcoma cell line.
|
11604227 |
2001 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
LncRNA TUG1 promotes the development of osteosarcoma through RUNX2.
|
31555384 |
2019 |
|
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Taken together, our results indicate that miR-302b functions as a tumour repressor in the invasion and migration of osteosarcoma by directly downregulating Runx2 expression and may be a potential therapeutic target for osteosarcoma.
|
29042587 |
2017 |
|
Osteosarcoma of bone
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Analysis of previously published OS aCGH data (GSE9654) and aCGH data from this study (GSE19180) identified significant deletion of WWOX in 30% (6/20) of OS samples, whilst significant increase in both RUNX2 and VEGFA gene copy numbers were detected in 55% (11/20) and 60% (12/20) of OS samples, respectively.
|
24330824 |
2013 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Intriguingly, runt-related transcription factor 2 (RUNX2) is expressed at higher level in numerous human cancers such as pancreatic cancer and osteosarcoma, indicating that, in addition to its pro-osteogenic role, RUNX2 has a pro-oncogenic potential.
|
29558908 |
2018 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, we suggest that the miR-205/RUNX2 axis may serve as a potential target for the treatment of OS.
|
27035764 |
2016 |
|
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of RUNX2 protected JQ1-sensitive OS cells from the effect of JQ1, and siRNA-mediated inhibition of RUNX2 sensitized the same cells to JQ1.
|
25307878 |
2015 |
|
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, the RUNX2 binding site, which encompasses positions ‑496 to ‑501 bp, was required to achieve maximal IPO8 promoter activity in Saos‑2 human osteosarcoma cells.
|
27277970 |
2016 |